Mucosal Responses to Minimally Invasive Pathogens
Mucosal Responses to Minimally Invasive Pathogens
批准号:
7757159
负责人:
LARS ECKMANN
金额:
$23.16万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-07-01 至 2014-06-30
关键词:
AblationAntigensB-LymphocytesCategoriesCell LineageCell physiologyCellsColitisConfocal MicroscopyDataDendritesDendritic CellsDevelopmentDiseaseEnvironmentEpithelialExposure toFoodFrequenciesGenetic ModelsGiardiaGiardia lambliaGiardiasisGoalsHealthImmuneImmune responseImmune systemImmunosuppressive AgentsImmunotherapyIn VitroInfectionInflammationInstructionInterleukin-10Interleukin-17IntestinesInvadedMedicalModelingMucosal ImmunityMucositisMucous MembraneMusParasitesPredispositionPrevention strategyPreventiveProcessProtozoan InfectionsReporterRoleSmall IntestinesSourceStagingSurfaceT-LymphocyteT-Lymphocyte SubsetsTherapeuticToll-like receptorsTransgenic OrganismsUnited StatesVaccinationWater SupplyWorkantimicrobialbasecytokinedesignenteric pathogenimprovedinsightmicrobialmicroorganism antigenminimally invasivepathogenpreventreceptorresponsesensortwo-photonwaterborne
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Constant exposure to harmless food antigens requires that intestinal immune responses are normally
biased towards tolerance and development of regulatory T cells, yet infections with intestinal pathogens
induce effector T cells and aggressive antimicrobial immune defenses. The mechanisms underlying the
differential recognition of harmless food antigens and threatening microbial antigens, and the corresponding
immune decision processes, are central to the understanding of mucosal immunity and its exploitation for
preventive and therapeutic medical strategies such as vaccination and immunotherapy. The
"reprogramming" from regulatory to effector T cells typically occurs in the context of inflammation initiated
by innate recognition of conserved microbial molecules through Toll-like receptors and other innate sensors.
However, the host mounts effective immune responses to certain enteric pathogens without mucosal
inflammation. An important pathogen of this category is the protozoan parasite, Giardia, which is a major
cause of diarrheal disease woridwide. It colonizes the lumen and epithelial surface of the small intestine,
and activates effective mucosal immune defenses, but does not invade the mucosa or cause significant
inflammation. The overall goal of our studies is to exploit Giardia as a model to elucidate the mechanisms
that govern immune decisions in the intestinal tract in the absence of inflammation. The studies have the
following Specific Aims: Aim 1. To determine the mechanisms of dendritic cell-dependent immune defense
against Giardia. Aim 2. To define the mechanisms of G/ard/a-triggered colitis in suseptible hosts. Aim 3. To
investigate the function of IL-17 in giardiasis. The proposed studies will generate important new insights into
the immune processes and decisions that take place in the intestinal tract at the interface of local resident
cells, innate immune cells, and professional immune cells of the T and B cell lineages in the context of a
protozoan infection. Furthermore, the work will provide a basis for the rational design of improved strategies
for treating and preventing giardiasis and possibly infection with other clinically important luminal
pathogens.
RELEVANCE (See instructions):
Giardia lamblia, a NIAID/CDC Category B priority pathogen, is a major cause of diarrheal disease woridwide
and the leading cause of waterborne disease in the United States. Giardia is highly contagious and a
credible threat to public water supplies and health. New insights into immune defenses against the parasite
will be important for designing improved treatment and prevention strategies against giardiasis.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Membrane-cloaked nanoparticles as mucosal vaccines against giardiasis
-
批准号:10495210
-
项目类别:
-
资助金额:$19.75万
-
财政年份:2021
-
负责人:LARS ECKMANN
-
依托单位:
Proteasome inhibitors against mucosal protozoan pathogens
-
批准号:10674897
-
项目类别:
-
资助金额:$64.84万
-
财政年份:2021
-
负责人:LARS ECKMANN
-
依托单位:
Proteasome inhibitors against mucosal protozoan pathogens
-
批准号:10367246
-
项目类别:
-
资助金额:$64.84万
-
财政年份:2021
-
负责人:LARS ECKMANN
-
依托单位:
Membrane-cloaked nanoparticles as mucosal vaccines against giardiasis
-
批准号:10351416
-
项目类别:
-
资助金额:$23.7万
-
财政年份:2021
-
负责人:LARS ECKMANN
-
依托单位:
San Diego Digestive Diseases Research Center
-
批准号:10395968
-
项目类别:
-
资助金额:$118.47万
-
财政年份:2019
-
负责人:LARS ECKMANN
-
依托单位:
San Diego Digestive Diseases Research Center
-
批准号:10617213
-
项目类别:
-
资助金额:$118.46万
-
财政年份:2019
-
负责人:LARS ECKMANN
-
依托单位:
Selective proteasome inhibitors for trichomoniasis
-
批准号:9806764
-
项目类别:
-
资助金额:$23.63万
-
财政年份:2019
-
负责人:LARS ECKMANN
-
依托单位:
Pilot and Feasibility Program
-
批准号:10395974
-
项目类别:
-
资助金额:$17.64万
-
财政年份:2019
-
负责人:LARS ECKMANN
-
依托单位:
Pilot and Feasibility Program
-
批准号:10617225
-
项目类别:
-
资助金额:$17.64万
-
财政年份:2019
-
负责人:LARS ECKMANN
-
依托单位:
High-potency nitro antimicrobials for topical treatment of trichomoniasis
-
批准号:9049219
-
项目类别:
-
资助金额:$35.39万
-
财政年份:2016
-
负责人:LARS ECKMANN
-
依托单位:
Next-generation 5-nitro heterocyclic antimicrobials against mucosal protists
-
批准号:8962082
-
项目类别:
-
资助金额:$63.74万
-
财政年份:2015
-
负责人:LARS ECKMANN
-
依托单位:
Next-generation 5-nitro heterocyclic antimicrobials against mucosal protists
-
批准号:9273358
-
项目类别:
-
资助金额:$62.37万
-
财政年份:2015
-
负责人:LARS ECKMANN
-
依托单位:
Mouse Model Core
-
批准号:7757167
-
项目类别:
-
资助金额:$15.55万
-
财政年份:2009
-
负责人:LARS ECKMANN
-
依托单位:
Click chemistry for novel antimicrobials against periodontal pathogens
-
批准号:7933971
-
项目类别:
-
资助金额:$47.62万
-
财政年份:2009
-
负责人:LARS ECKMANN
-
依托单位:
Click chemistry for novel antimicrobials against periodontal pathogens
-
批准号:7819386
-
项目类别:
-
资助金额:$48.54万
-
财政年份:2009
-
负责人:LARS ECKMANN
-
依托单位:
The UCSD Digestive Diseases Research Development Center
-
批准号:7789482
-
项目类别:
-
资助金额:$54.08万
-
财政年份:2008
-
负责人:LARS ECKMANN
-
依托单位:
The UCSD Digestive Diseases Research Development Center
-
批准号:8053901
-
项目类别:
-
资助金额:$50.21万
-
财政年份:2008
-
负责人:LARS ECKMANN
-
依托单位:
The UCSD Digestive Diseases Research Development Center
-
批准号:8268140
-
项目类别:
-
资助金额:$50.21万
-
财政年份:2008
-
负责人:LARS ECKMANN
-
依托单位:
Next-generation 5-nitroimidazoles against giardiasis
-
批准号:8116019
-
项目类别:
-
资助金额:$103.63万
-
财政年份:2007
-
负责人:LARS ECKMANN
-
依托单位:
Mucosal Responses to Minimally Invasive Pathogens
-
批准号:7509283
-
项目类别:
-
资助金额:$18.56万
-
财政年份:2007
-
负责人:LARS ECKMANN
-
依托单位:
国内基金
海外基金
Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
-
批准号:2022J011295
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:王亚伟
-
依托单位:
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究
-
批准号:30801055
-
项目类别:青年科学基金项目
-
资助金额:19.0万元
-
批准年份:2008
-
负责人:王丽梅
-
依托单位: